ASX Announcement / Media Release

29 October 2019

OncoSil Medical Limited

2019 Annual General Meeting Results

Sydney, Australia – 29 October 2019:

The following resolutions were considered at the Annual General Meeting of members of OncoSil Medical Limited on 29 October 2019 and passed by the requisite majorities:

Resolutions decided on a poll:

RESOLUTION 1 – Adoption of the Remuneration Report

RESOLUTION 2 – Re-election of Dr Martin Cross as a Director

RESOLUTION 3 – Election of Mr Michael Bassett as a Director

Resolution 4 was withdrawn at the meeting.

A summary of proxy votes and the number of votes cast on each poll is attached in accordance with Listing Rule 3.13.2 and as required by Section 251AA(2) of the Corporations Act 2001 (Cth).

ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL
Suite 402, Level 4, 50 Berry Street, North Sydney, NSW 2060 AUSTRALIA
TELEPHONE +61 2 9223 3344 FACSIMILE +61 2 9252 3988
WEB www.oncosil.com.au

OncoSil Medical Ltd
Annual General Meeting
Tuesday, 29 October 2019
Voting Results

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth).

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	**Resolution Type**	**For**	**Against**	**Proxy's Discretion**	**Abstain**	**For**	**Against**	**Abstain***	**Carried / Not Carried**
1. Adoption of Remuneration Report	Ordinary	81,284,620 92.08%	3,771,883 4.27%	3,218,499 3.65%	6,679,947	93,219,377 96.04%	3,841,883 3.96%	7,702,947	Carried
2. Re-election of Dr Martin Cross as Director	Ordinary	131,532,782 96.57%	1,021,440 0.75%	3,653,009 2.68%	6,230,932	144,960,049 99.28%	1,056,440 0.72%	6,230,932	Carried
3. Election of Mr Michael Bassett as Director	Ordinary	131,467,246 96.52%	1,086,976 0.80%	3,653,009 2.68%	6,230,932	143,871,513 99.23%	1,121,976 0.77%	7,253,932	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

-ENDS-

Company	Media
Mr Daniel Kenny CEO & Managing Director E: daniel.kenny@oncosil.com.au T: +61 2 9223 3344	**Arthur Chan** WE Buchan E: arthurc@we-buchan.com M: 0404 369 388

About OncoSil

OncoSil Medical is a medical device company seeking to advance radiation for cancer patients. OncoSil Medical's lead product, OncoSil™ is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient's pancreatic tumours via an endoscopic ultrasound.

Treatment with the OncoSil™ is intended to deliver more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has conducted four clinical studies with encouraging results on tolerability, safety and efficacy. A CE Mark application to commercially sell OncoSil™ in the European Union (EU) is under review.

The U.S Food and Drug Administration granted an Investigational Device Exemption (IDE) in July 2016 with approval to conduct a clinical study of the OncoSil™ device. The aim of the study will be to collect safety and effectiveness data required to support a Premarket Approval (PMA) application.

An Investigational Device Exemption (IDE) has been granted by the United States Food and Drug Administration (FDA) to conduct a clinical study of the OncoSil™ device aimed at supporting a PMA approval. Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012, 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world- wide market opportunity for OncoSil™ in pancreatic cancer exceeds $1b.

Hepatocellular carcinoma (HCC) or liver cancer, is the 6th most common cancer in the world with 782,000 new cases diagnosed in 2012. While hepatocellular carcinoma can be treated by surgery or transplantation, the majority of patients with HCC have disease which is too advanced for surgery and their survival ranges from a few months to two or more years. The value of the hepatocellular cancer market is expected to triple in size to $1.4b by 2019.

Forward Looking Statements

This document contains certain forward-looking statements, relating to OncoSil's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements

involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil Medical is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.